基质消融对比抗心律失常药物治疗症状性室性心动过速
SURVIVE-VT 试验将 144 例缺血性心肌病且已植入 ICD 的症状性室速患者随机分为导管消融组或抗心律失常药物组。24 个月时,消融组主要复合终点发生率为 28.2%,药物组为 46.6%(HR 0.52,95%CI 0.30-0.90,P=0.021),差异主要由严重治疗相关并发症减少驱动。
要点
- 缺血性心肌病合并 ICD 的症状性室速患者,导管消融较抗心律失常药物显著降低主要复合终点。
- 复合终点差异主要来自严重治疗相关并发症的显著减少(9.9% vs 28.8%)。
- 两组心脏死亡率无显著差异,心力衰竭住院风险无统计学差异。
核心结论
- 在缺血性心肌病合并 ICD 的症状性室速患者中,导管消融较抗心律失常药物降低心血管死亡、适当 ICD 放电、心衰住院或严重治疗相关并发症的复合终点。
研究设计与样本
- SURVIVE-VT 为前瞻性、多中心、随机试验,纳入缺血性心肌病且有适当 ICD 放电的患者,1:1 随机至完整心内膜基质消融或抗心律失常药物治疗。
- 共随机 144 例患者(中位年龄 70 岁,96% 男性),消融组 71 例,抗心律失常药物组 73 例。
- 抗心律失常药物包括胺碘酮联合 β 受体阻滞剂、单用胺碘酮或索他洛尔联合/不联合 β 受体阻滞剂。
主要发现
- 24 个月时主要复合终点在消融组发生率为 28.2%,抗心律失常药物组为 46.6%(HR 0.52,95%CI 0.30-0.90,P=0.021)。
- 严重治疗相关并发症在消融组为 9.9%,药物组为 28.8%(HR 0.30,95%CI 0.13-0.71,P=0.006)。
- 心衰住院在消融组 8 例,药物组 13 例(HR 0.56,95%CI 0.23-1.35,P=0.198)。
- 心脏死亡率两组无差异(HR 0.93,95%CI 0.19-4.61,P=0.929)。
临床怎么用
- 对于缺血性心肌病合并 ICD 且出现症状性室速的患者,可考虑将导管消融作为一线治疗选择以降低复合不良事件风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator (ICD), catheter ablation and antiarrhythmic drugs (AADs) reduce ICD shocks, but the most effective approach remains uncertain. OBJECTIVES: This trial compares the efficacy and safety of catheter ablation vs AAD as first-line therapy in ICD patients with symptomatic ventricular tachycardias (VTs). METHODS: The SURVIVE-VT (Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia) is a prospective, multicenter, randomized trial including patients with ischemic cardiomyopathy and appropriated ICD shock. Patients were 1:1 randomized to complete endocardial substrate-based catheter ablation or antiarrhythmic therapy (amiodarone + beta-blockers, amiodarone alone, or sotalol ± beta-blockers). The primary outcome was a composite of cardiovascular death, appropriate ICD shock, unplanned hospitalization for worsening heart failure, or severe treatment-related complications. RESULTS: In this trial, 144 patients (median age, 70 years; 96% male) were randomized to catheter ablation (71 patients) or AAD (73 patients). After 24 months, the primary outcome occurred in 28.2% of patients in the ablation group and 46.6% of those in the AAD group (hazard ratio [HR]: 0.52; 95% CI: 0.30-0.90; P = 0.021). This difference was driven by a significant reduction in severe treatment-related complications (9.9% vs 28.8%, HR: 0.30; 95% CI: 0.13-0.71; P = 0.006). Eight patients were hospitalized for heart failure in the ablation group and 13 in the AAD group (HR: 0.56; 95% CI: 0.23-1.35; P = 0.198). There was no difference in cardiac mortality (HR: 0.93; 95% CI: 0.19-4.61; P = 0.929). CONCLUSIONS: In ICD patients with ischemic cardiomyopathy and symptomatic VT, catheter ablation reduced the composite endpoint of cardiovascular death, appropriate ICD shock, hospitalization due to heart failure, or severe treatment-related complications compared to AAD. (Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia [SURVIVE-VT]: NCT03734562).
引用
- Arenal Á, Ávila P, Jiménez-Candil J, et al. Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia. J Am Coll Cardiol. 2022. PMID: 35422240. doi:10.1016/j.jacc.2022.01.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。